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Abstract
Dry powder inhalers (DPIs) are widely used in the clinical practice for delivering therapeutics to patients with lung
diseases, such as chronic obstructive pulmonary disease. An overview of current DPIs available on the market from
high resistance to low resistance has been reported in a recent review article. We assessed this concept review
article and believe this letter provides important additional information regarding the correct interpretation of the
data on low resistance DPIs.
Correspondence
Dear Editors,
A review by Dal Negro (April’s edition of Multidisciplin-
ary Respiratory Medicine Journal) addressed the topic of
dry powder inhalers (DPIs) and factors regarding their
effectiveness in the delivery of treatment [1]. While the
concept of this article in reviewing and discussing the
array of different DPI devices available is welcomed, the
author’s interpretation of the data leading to the conclu-
sion that low resistance DPIs, unlike those with higher re-
sistance, should not be regarded as optimally performing
DPI is questionable. This we believe is due to a different
perspective of the published data surrounding this type of
DPI which can potentially mislead some readers.
The author describes the main characteristics of DPIs
and suggests that the performance of a DPI is only af-
fected by two main driving factors, the inspiratory flow
rate of the patient and the turbulence produced inside the
device. While the author might be trying to simplify this
topic for the reader, this statement is inaccurate and does
not truly reflect the reality that numerous factors, as well
as the inhalation, can impact the performance of a DPI, all
of which have been well documented in the literature (ex-
cipients [2], drug substance and formulation [3]).
The authors’ main statement that low resistance DPIs
require a higher inspiratory airflow rate and effort is not
accurate and can be misleading. The major flaw in the
review is that the author has misunderstood that it is the
turbulent force, that is generated inside a DPI during
inhalation to de-aggregate the formulation, is created by
the interaction between the patient’s inspiratory effort
and the resistance of the device [4]. For a set inspiratory
effort, therefore, the inhalation flows when using a low
resistance DPI will be greater than when using a DPI
with a higher resistance. For example, using the same
patients, a mean peak inspiratory flow (PIF) of 72 L/min
was generated with the Breezhaler® device compared
with a mean PIF of only 36 L/min with the HandiHaler®,
a device of significantly higher airflow resistance [5]. The
resultant turbulent force, inside the two devices, will be
similar [6]. The other two inhalation related factors that
affect the de-aggregation of the dose are the inhaled
volume required to empty the dose out of the device,
and finally, the length of the inhalation channel within
the DPI. It is beyond the scope of this letter to discuss
these two factors.
The perception of suboptimal particle disaggregation
with low resistance DPIs at lower flow rates does not
hold true. In fact data published for glycopyrronium and
indacaterol demonstrated there was consistent dose de-
livery performance from Breezhaler® using airflow rates
between 50–100 L/min [5, 7]. Similarly, consistent dose
delivery across a range of inspiratory flow profiles has
also been shown for a DPI with higher resistance [8].
The author reviews several DPIs (low, mid and high
resistance) and states that for the low resistance DPI
Breezhaler® device, a PIF rate of 111 L/min is ‘required’
which is not the case. Published data shows that patients
with mild to very severe chronic obstructive pulmonary
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disease (COPD) were able to generate, on average, a PIF
rate of 94.8 L/min (range, 52–133 L/min) [7]. Consistent
dose delivery from the Breezhaler® device has been re-
ported within the relevant range of flow rates above, cor-
responding to a reported minimum PIF of 52 L/min or
more achieved by all studied COPD patients [7]. It does
not mean that such rates are required to actuate the
Breezhaler® device successfully in order to successfully de-
liver the medication.
The inspiratory efforts required by patients’ needs to be
considered only when a minimum inhalation flow through
a specific DPI is required for efficient de-aggregation to
occur [9]. This is not the case with the low resistance DPI
Breezhaler® device, as patients were able to achieve the
minimum flow required. But when the resistance of the
DPI is higher (for example Handihaler® [5, 10], Turboha-
ler® [11]), then sufficient inspiratory effort to generate the
minimum flow (approximately 30 L/min for both the
Handihaler® [12] and Turbohaler® devices [13]) for effi-
cient de-aggregation requires consideration. This may
be a problem for those who have more severe disease
because their inspiratory effort is reduced and thus they
have challenges in generating the required threshold
flow rate [4, 11, 14].
To conclude, Dal Negro has not accurately represented
the data on low resistance DPIs. We hope this letter





Thank you for allowing me to reply to this letter.
I have read the Letter to the Editor of Multidisciplinary
Respiratory Medicine by H. Chrystyn and D. Price with
attention, and concerning my recent review on “Dry
Powder Inhalers and the right things to remember: a
concept review”. First of all, I would like to amend the
Authors’ assumption when they report that the review is
stating that the high resistance DPIs should be regarded
as the optimally performing devices in terms of their
inhalation effectiveness. Actually, in the text of the re-
view is clearly written that “only when the inhalation
flow rate and the DPI intrinsic resistance are balanced,
the inhalation is optimized”. This condition practically
corresponds to that of medium resistance devices (and
not of that of high resistance ones), even though also a
range of conditions exists among the family of medium
resistance DPIs (such as, some DPIs are positioned
closer to the lower and some other to the upper limits
of the medium resistance regimen – see Table 2 in the
review). The meaning of this assertion in the review is
quite different from what interpreted and reported by
the Authors in their letter, likely mis-understanding the
real philosophy of the review itself. Secondly, the review
stems from recent and consolidated evidences in the
literature which are clearly confirming that the two
main factors (even not the unique ones, as specified also
in the review, pag. 4) are represented by the patient’s
lung performance and the intrinsic resistance of the DPI
(see references). On the other hand, the mechanism of
dispensing powder from a DPI is a function of the
Turbulent Energy, according to the following relation-
ship: √P= Q x R, where Q is the inhalation flow and R is
the inhaled resistance. Not by chance, when the flow
rate is measured at a pressure drop of 4.0kPa, which
corresponds to the pressure drop for DPIs testing, the
inspiratory flow rate needed by low resistance DPIs is
much higher than that of medium, and obviously even
more of that of high resistance DPIs (Al-Showair et al.-
Respir Med, 2007). Finally, I would like to emphasize
that the review is absolutely independent: actually, dif-
ferently from the letter, all DPI brands reported are
equally mentioned within the review, and no brand was
privileged in terms of n. of mentions in the text. In con-
clusion, I am convinced that the review should be
regarded as a convenient tool which contributes to re-
fresh some basic (frequently forgotten) factors crucially
modulating the DPIs’ performance. It would also pro-
vide physicians with some concepts which could sup-
port their choices in clinical practice, but stemming
from a more independent basis.
Roberto W. Dal Negro
National Center for Respiratory Pharmacoeconomics
and Pharmacoepidemiology - CESFAR, Verona, Italy
Research & Clinical Governance, Verona, Italy
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